CDSCO to Launch Integrated Digital Drug Regulatory Platform Within 18 Months, Piloting AI to Slash Processing Times
核心洞察
India's CDSCO (搜索) will roll out the first phase of a new end-to-end Digital Drug Regulatory System (DDRS) within 18 months, creating a unified platform for all regulatory stakeholders.
The platform will connect the entire pharmaceutical value chain—from clinical development and manufacturing to approvals, distribution, and post-market surveillance—on a single digital ecosystem.
CDSCO (搜索) is piloting artificial intelligence for automated reviewer allocation and application pre-screening, aiming to reduce first-response time by 80% and overall processing time by 40%.
India's Central Drugs Standard Control Organisation (CDSCO (搜索)) is set to launch the first phase of a comprehensive digital drug regulatory platform within the next 18 months, a move that promises to transform how pharmaceutical manufacturers, distributors, and regulators interact across the country's drug oversight system.
Speaking at the Global Drug Regulatory Conclave (GDRC) 2026 in New Delhi, Drugs Controller General of India (DCGI) Dr. Rajeev Singh Raghuvanshi announced that the new Digital Drug Regulatory System (DDRS) will provide an end-to-end integrated interface, enabling interoperability among all regulatory stakeholders. The expression of interest for the technology vendor has already been issued, with the selection process currently underway.
"The new platform will offer an end-to-end integrated system, enabling interoperability among all regulatory stakeholders while also bringing manufacturers, distributors and pharmacovigilance experts onto a unified digital platform," Dr. Raghuvanshi stated during his presentation.
A Unified Ecosystem Across the Pharmaceutical Value Chain
The DDRS is designed to connect the entire pharmaceutical regulatory value chain—from research and clinical development through manufacturing, approvals, distribution, and post-market surveillance. Central and state regulators, manufacturers, and other stakeholders will operate on a common digital ecosystem, allowing regulators to monitor the complete product lifecycle from initial filings and regulatory submissions to post-market safety surveillance.
A key feature of the platform will be visibility indicators that track companies' compliance records, including past instances of Not of Standard Quality (NSQ) products and GMP audit outcomes. This functionality is intended to help procurement agencies make more informed assessments when evaluating tender bids.
For industry, the platform will provide a single-window interface for various regulatory compliances and will digitise the entire process to improve processing timelines. Dr. Raghuvanshi noted that nearly 99 per cent of CDSCO (搜索)'s regulatory functions are already being carried out online, and the new system builds on this existing digital foundation.
AI-Powered Regulatory Processing
In a significant technological advancement, CDSCO (搜索) is piloting artificial intelligence and a digital ticketing system to automate reviewer allocation and enable pre-screening of applications. According to Dr. Raghuvanshi, these AI-driven tools are expected to decrease first-response time by 80 per cent and reduce overall processing time by 40 per cent, marking a substantial acceleration in regulatory workflows.
QR Code Authentication Already Delivering Results
The regulator has already begun issuing Certificates of Pharmaceutical Product (CoPP) and current Good Manufacturing Practice (cGMP) certificates with QR codes to enable digital authentication. Dr. Raghuvanshi highlighted that this initiative allows overseas regulators to instantly verify certificate authenticity, helping exporters "save up to six months" that was previously spent obtaining necessary clearances for registering products in overseas markets.
Broader Regulatory Transformation
The digital platform is part of a wider regulatory modernization effort. Dr. Raghuvanshi outlined that CDSCO (搜索) has streamlined its export regulatory framework through a fully digitised export No Objection Certificate (NOC) system and has introduced globally aligned regulatory reliance mechanisms and accelerated approval pathways. He further noted that nearly 25 to 30 per cent of clinical trials are currently being considered for waiver for eligible innovative products under the evolving regulatory framework.
Support for emerging technologies is also expanding. The MedTech Mitra initiative has already assisted more than 800 startups in navigating regulatory pathways, and similar facilitation mechanisms are being planned for biologics and other advanced technologies.
Government Leadership Weighs In
In his virtual address at GDRC 2026, Union Minister for Health and Family Welfare Jagat Prakash Nadda emphasized that India is building a future-ready drug regulatory framework that supports healthcare innovation while maintaining standards of patient safety, quality, and efficacy.
"India's pharmaceutical industry is progressing from being a global supplier of affordable generic medicines to becoming a centre for pharmaceutical innovation," Nadda said, adding that as healthcare advances toward biologics, biosimilars, gene therapies, precision medicine, AI-assisted drug development, and digital therapeutics, India's regulatory framework must evolve simultaneously.
Mohit Yadav, Joint Secretary, Department of Commerce, Export Promotion (Pharma), underscored the importance of regulatory modernization for trade: "For pharmaceuticals, regulation is the true border. Faster, transparent, and predictable pathways can improve patient access without lowering standards."
Namit Joshi, Chairman of Pharmexcil (搜索), noted that the GDRC 2026 would provide a platform for regulators and industry to work toward harmonised standards and consistent compliance, "strengthening confidence in Indian pharmaceuticals across global markets."
The GDRC 2026, organised by CDSCO (搜索) in association with Pharmexcil (搜索), brought together regulatory officials from more than 40 countries, including the US, UK, and Japan, with discussions focused on strengthening regulatory cooperation, advancing digital transformation, and promoting regulatory science to improve timely access to safe, effective, and affordable medicines.